Premium
Mechanisms of levamisole‐induced granulocytopenia in breast cancer patients
Author(s) -
Vogel Charles L.,
Silverman Michael A.,
Mansell Peter W.,
Miller Alan M.,
Thompson John S.,
Herbick John M.,
Brunskill Dennis E.,
Padgett Darlene C.,
McKinney E. Churchill,
Sugarbaker Everett V.
Publication year - 1980
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830090205
Subject(s) - levamisole , chemoimmunotherapy , medicine , bone marrow , breast cancer , chemotherapy , cyclophosphamide , granulocyte , immunology , oncology , cancer
Five of 39 (13%) women treated with adjuvant combination chemotherapy plus levamisole immunotherapy after mastectomy for Stage II or III breast cancer developed levamisole‐induced granulocytopenia. This complication occurred in each of the women between six and ten weeks after the completion of six months of combination chemoimmunotherapy when they were taking levamisole alone. Although none of the patients had an HLA B‐27 locus and leukoagglutinins could not be demonstrated, complement‐dependent, IgM mediated, peripheral destruction of granulocytes was documented using a microgranulocytotoxicity assay. In addition, a factor(s) present in serum from patients developing levamisole‐induced granulocytopenia caused suppression of bone marrow granulocyte progenitor cells (CFU‐C). The possible relationships between levamisole‐induced peripheral granulocyte destruction and bone marrow CFU‐C suppression are discussed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom